Preventing infant HIV infections in Malawi
Preventing Infant Infections with Implementation Science in Malawi
['FUNDING_P01'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-11325791
This program will try new ways to stop mothers from getting HIV during pregnancy and breastfeeding and to keep pregnant and breastfeeding women with HIV linked to care in Malawi.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-11325791 on ClinicalTrials.gov |
What this research studies
You could be invited to join one of three clinical projects aimed at stopping mothers from acquiring HIV and protecting their babies. One project will track people who use oral or injectable PrEP during pregnancy and breastfeeding, including a national registry and a safety cohort. Other projects focus on finding and re-engaging pregnant and postpartum women with HIV who have been missed by routine care, using implementation strategies and data-driven approaches. Local clinics, an implementation science team, and a data core will work together to deliver and monitor these efforts.
Who could benefit from this research
Good fit: Pregnant or breastfeeding women in Malawi who are HIV-negative and considering or using PrEP, or women living with HIV during pregnancy/postpartum who may have missed or disengaged from care, are the primary candidates.
Not a fit: People who are not pregnant or breastfeeding, those living outside Malawi, or those not receiving care at participating clinics are unlikely to be eligible or benefit directly.
Why it matters
Potential benefit: If successful, the program could lower new maternal HIV infections and reduce the number of infants born with HIV by improving prevention and care during pregnancy and breastfeeding.
How similar studies have performed: Daily oral TDF/FTC PrEP has helped prevent HIV in other groups, while long-acting injectable cabotegravir is promising but has limited safety data in pregnancy, so this program addresses an important evidence gap.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HOSSEINIPOUR, MINA CHRISTINE — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: HOSSEINIPOUR, MINA CHRISTINE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus